DDInter463 DDInter1055
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Dacarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Dacarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Dacarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Dacarbazine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Dacarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Ciprofloxacin
Ciprofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Dacarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Dacarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Dacarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Lomefloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Dacarbazine {u} (Compound) treats {v} (Disease) melanoma
melanoma {u} (Disease) downregulates {v} (Gene) SDC1
SDC1 {u} (Gene) is downregulated by {v} (Compound) Levofloxacin
Dacarbazine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Levofloxacin (Compound)
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Levofloxacin (Compound)
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Levofloxacin (Compound)
Dacarbazine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Levofloxacin (Compound)
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Ciprofloxacin (Compound) and Ciprofloxacin (Compound) resembles Levofloxacin (Compound)
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)
Dacarbazine (Compound) treats melanoma (Disease) and melanoma (Disease) downregulates SDC1 (Gene) and SDC1 (Gene) is downregulated by Levofloxacin (Compound)
Dacarbazine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Enoxacin (Compound) and Enoxacin (Compound) resembles Levofloxacin (Compound)